Funding
Cloverleaf Bio raises USD 33M seed for engineered tRNA cancer therapeutics
Key Facts
Signal Type
Funding
Industry
Biotech
Companies
Cloverleaf Bio, 4BIO Capital, AbbVie Ventures, Eli Lilly, Boehringer Ingelheim Venture Fund
Date
September 8, 2026
Connecticut-based Cloverleaf Bio raised $33 million in an oversubscribed seed round to advance its engineered tRNA-based oncology platform. The round was led by 4BIO Capital and included strategic investments from AbbVie Ventures, Eli Lilly and Company, Boehringer Ingelheim Venture Fund, alongside Draper Associates, Mission BioCapital, and American Cancer Society BrightEdge.
Proceeds will support the lead inhibitory tRNA asset, CLB-001, toward early clinical testing in hepatocellular carcinoma (HCC), and preclinical development of an antibody-tRNA conjugate (ATC) targeting colorectal cancer. The company also previously received non-dilutive support through an NCI SBIR grant and a Lilly Genetic Medicine Grand Challenge award.
Cloverleaf Bio directly benefits from new capital to scale its team and move toward clinical trials. The company is a Yale University spinout founded by CEO Austin Draycott, CSO Cole Lewis, and SAB Chair Wendy Gilbert. Strategic pharma investors (AbbVie, Lilly, Boehringer) gain early access to a novel platform targeting RNA-modifying enzymes in oncology.
Vendors of clinical trial management software, CRO services, lab informatics, and preclinical research tools should consider this a new business opportunity as Cloverleaf expands operations to support IND-enabling studies.
The round signals continued investor appetite in tRNA-based therapeutics and RNA-modifying enzyme targets. The oversubscribed seed with three pharma strategic backers provides strong validation of the platform's potential beyond oncology (neurodegenerative and fibrotic diseases).
Monitor Cloverleaf's progress toward IND-enabling studies for CLB-001 in HCC and whether the ATC program advances into animal models. Watch for further non-dilutive funding from NCI or expansion of the platform into non-oncology indications like neurodegeneration and fibrosis.
Also track hiring of clinical development and regulatory roles, a strong signal of imminent trial initiation. Any new strategic collaborations or follow-on funding from existing pharma backers would further validate the platform.
Source:
AllSciGet biotech signals in your CRM
FDA approvals and rejections, clinical trial results, pharma M&A, drug recalls, and funding rounds.
